{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:29:33Z","timestamp":1753892973403,"version":"3.41.2"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2023.1248878","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:37:02Z","timestamp":1693535822000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum HBV RNA: a promising biomarker for blood product safety screening and enhanced diagnostic efficiency in chronic hepatitis B virus infection"],"prefix":"10.3389","volume":"11","author":[{"given":"Sulan","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2471\/BLT.08.065722","article-title":"Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?","volume":"88","author":"Clements","year":"2010","journal-title":"Bulletin of the World Health Organization."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1080\/22221751.2020.1840311","article-title":"Yin-Yang 1 and HBx protein activate HBV transcription by mediating the spatial interaction of cccDNA minichromosome with cellular chromosome 19p13","volume":"9","author":"Shen","year":"2020","journal-title":"11 Emerging Microbes & Infections."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1016\/S2352-3026(19)30200-5","article-title":"The global need and availability of blood products: a modelling study","volume":"6","author":"Roberts","year":"2019","journal-title":"Lancet Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.3201\/eid2607.200839","article-title":"Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations","volume":"26","author":"Chang","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s12072-019-09966-z","article-title":"Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers","volume":"13","author":"Nishida","year":"2019","journal-title":"Hepatol Int"},{"key":"B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","article-title":"Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy","volume":"133","author":"Kusumoto","year":"2019","journal-title":"J Am Soc Hematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06468-y","article-title":"Characteristic of HBV nucleic acid amplification testing yields from blood donors in China","volume":"21","author":"Wu","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","article-title":"Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy","volume":"56","author":"Mak","year":"2021","journal-title":"J Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/cld.774","article-title":"Serum hepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection","volume":"13","author":"Cloherty","year":"2019","journal-title":"Clin Liver Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JCM.01275-19","article-title":"Diagnostic value of detection of pregenomic RNA in sera of hepatitis B virus-infected patients with different clinical outcomes","volume":"58","author":"Lin","year":"2020","journal-title":"J Clin Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/hep.29872","article-title":"Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment","volume":"68","author":"Van Campenhout","year":"2018","journal-title":"Hepatology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1002\/hep.32018","article-title":"Comparison of HBV RNA and Hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America","volume":"74","author":"Ghany","year":"2021","journal-title":"Hepatology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/22221751.2022.2045874","article-title":"A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients","volume":"11","author":"Yu","year":"2022","journal-title":"Emerg Microbes Infect."},{"key":"B15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in, chronic hepatitis B and D-Report from the 2022 AASLD-EASL HBV\/HDV Treatment Endpoints Conference","volume":"15","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1248878\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:37:05Z","timestamp":1693535825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1248878\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":16,"alternative-id":["10.3389\/fpubh.2023.1248878"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1248878","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1248878"}}